CD274 and neoplasm: In contrast, monotherapy with durvalumab (anti-PD-L1) did not produce a significant difference in tumor size between the GSDME-KO and GSDME-NC groups (Figure 6B), mirroring the repeated failure of PD-L1 inhibitor monotherapy in SCLC clinical settings.